Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Merck To Test Cancer Drug With Rivals …
by Michael McCoy
February 10, 2014
| A version of this story appeared in
Volume 92, Issue 6
Merck & Co. has signed clinical research pacts with three rival companies to evaluate combinations of their drugs with MK-3475, a Merck antibody in development as a cancer immunotherapy. Merck will study MK-3475 in combination with Pfizer’s small-molecule kinase inhibitor Inlyta. The firm will investigate a combination of MK-3475 with Incyte’s investigational immunotherapy INCB24360. And Merck will test its drug with talimogene laherparepvec, an Amgen drug now in development. FDA dubbed MK-3475 a breakthrough therapy last year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X